January 11, 2015 | Protalix Biotherapeutics announced positive results in the trials of a drug for the treatment of Fabry Disease, after which the company’s shares saw a 12 percent spike. The results on 3 patients with Fabry Disease, a rare lysosomal storage disease, demonstrated significant clinical effectiveness, even at a low dosage of the drug. The results showed what the company reports to be a 78.8 percent decrease in the effect of pain on a patient’s daily functions, as well as stable heart and kidney function. The complete results of the study are set to be published by the close of 2015. Protalix was founded in 1993 by Yoseph Shaaltiel and is currently headed by CEO and President David Aviezer.